Patents Examined by Marcia S. Noble
  • Patent number: 11674157
    Abstract: Certain donor plasmid vectors such as pFastBac™1 and pFastBac™ Dual lack a cis DNA element upstream of the polh translation start codon (ATG) present in wild type (wt) Autographa californica multiple nucleopolyhedrovirus (AcMNPV), and contain a SV40 pA fragment. When a cis DNA element is inserted upstream of the 50 bp polh promoter and SV40 pA was replaced with a AcMNPV polh pA signal in pFastBac™1 and pFastBac™Dual, certain protein expression levels in High Five™ cells using the Bac-to-Bac® system reached that of the wt AcMNPV.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: June 13, 2023
    Assignee: Miami University
    Inventors: Xiao-Wen Cheng, Hui Shang, Tyler Garretson
  • Patent number: 11661582
    Abstract: The electrical pacemakers currently being used for the therapeutic approaches for treatment of “sick sinus syndrome” are not hormonally regulatable and entail risks through infections or premature battery discharge. These problems could be overcome by means of “biological cardiac pacemakers” obtained from pluripotent stem cells (PSCs). It has been shown that the controlled differentiation of stem cells with TBX, inductors of sinoatrial node cells, and an additional Myh6 promoter-specific antibiotic selection can give cardiomyocyte aggregates consisting to an extent of more than 80% of physiologically functional pacemaker cells. These induced sinoatrial bodies (“iSABs”) for the first time exhibited very high beat frequencies (300-400 bpm), similar to those in a murine heart, and were able to stably rhythmically stimulate heart muscle cells ex vivo.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: May 30, 2023
    Inventors: Robert David, Julia Jung
  • Patent number: 11654201
    Abstract: Described are nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These are particularly useful for applications using gene therapy.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: May 23, 2023
    Assignees: VIB VZW, Universiteit Gent, Life Sciences Research Partners VZW
    Inventors: Marinee Chuah, Thierry Vandendriessche, Pieter De Bleser
  • Patent number: 11655459
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: May 23, 2023
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Patent number: 11654428
    Abstract: Described herein are methods, systems and apparatus for separating components of a biological sample; as well as methods of using compositions prepared by same.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: May 23, 2023
    Inventors: Sanjay Batra, Elizabeth G. Cellucci, Justin Joseph Batra, Jaya Krishna Rose Batra
  • Patent number: 11653635
    Abstract: The invention relates to methods of increasing the genetic progress of a line, breed or herd of swine through the use of sex-selected sperm cells in artificial insemination techniques. The invention also encompasses methods of artificially inseminating a swine via deep intrauterine catheter or via a laparoscopic procedure, which allow the use of reduced doses of sex-selected sperm cells.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 23, 2023
    Assignee: Inguran, LLC
    Inventors: Juan Moreno, Gregg Bevier, John Dobrinsky
  • Patent number: 11634728
    Abstract: The present invention relates to an AAV vector carrying a predetermined hybrid HGF gene sequence. Use of the AAV vector of the present invention allows a hybrid HGF gene to be delivered to a subject at a high delivery yield.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: April 25, 2023
    Assignee: HELIXMITH CO., LTD
    Inventors: Seung Shin Yu, Jae Gyun Jeong, Jung Hun Lee, Su Bin Kim
  • Patent number: 11634732
    Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: April 25, 2023
    Inventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
  • Patent number: 11629132
    Abstract: The present invention provides methods of inducing proliferation of and/or differentiating cells comprising contacting cells with compounds within the methods of the invention. The present invention further provides cells obtainable by the methods of the invention.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: April 18, 2023
    Inventors: Sangeeta Bhatia, Jing Shan, Michelle Palmer, Nathan Ross
  • Patent number: 11618910
    Abstract: Methods and systems for the production of one or more products from a gas stream produced in a methanol production process. The method comprises converting at least a portion of a methane feedstock to a substrate comprising CO and H2. The substrate comprising CO and H2 is anaerobically fermented in a bioreactor to produce one or more alcohols. The method and system may further include process for the production of methanol processes for the production of acetic acid.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: April 4, 2023
    Assignee: LanzaTech NZ, Inc.
    Inventor: Michael Anthony Schultz
  • Patent number: 11612150
    Abstract: In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: March 28, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Adam P. Silverman, Joy Yu Zuchero
  • Patent number: 11591381
    Abstract: The present invention relates to, inter alia, an engineered cell (e.g., iPSC, IPS-derived NK, or NK cell) comprising a disrupted B2M gene and an inserted polynucleotide encoding one or more of SERPINB9, a fusion of IL15 and IL15R?, and/or HLA-E. The engineered cell can further comprise a disrupted CIITA gene and an inserted polynucleotide encoding a CAR, wherein the CAR can be an anti-BCMA CAR or an anti-CD30 CAR. The engineered cell may further comprise a disrupted ADAM17 gene, a disrupted FAS gene, a disrupted CISH gene, and/or a disrupted REGNASE-1 gene. Methods for producing the engineered cells are also provided, and therapeutic uses of the engineered cells are also described. Guide RNA sequences targeting described target sequences are also described.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: February 28, 2023
    Inventors: Valentin Sluch, Alireza Rezania, Jason Sagert, Danielle Swain
  • Patent number: 11591564
    Abstract: Compositions useful for propagation of pluripotent stem cells are provided. The compositions comprise a polysaccharide hydrogel linked to a peptide fragment of the extracellular domain of epithelial cadherin. Methods of making the composition, and culturing pluripotent stem cells also are provided.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 28, 2023
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ipsita Banerjee, Prashant Kumta, Thomas Richardson
  • Patent number: 11584917
    Abstract: The present invention relates to a chemically defined medium for eukaryotic cell culture, comprising water, at least one carbon source, one or more vitamins, one or more salts, one or more growth factors, one or more fatty acids, one or more buffer components, selenium and one or more further trace elements and its use in the culture of cancer stem cells, in particular tumorsphere culture of cancer stem cells.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: February 21, 2023
    Assignee: PROMOCELL GMBH
    Inventor: Hagen Wieland
  • Patent number: 11564999
    Abstract: The present invention provides for the intratumoral delivery of at least one immunostimulatory cytokine in combination with at least one checkpoint inhibitor. In particular, it provides delivery of a plasmid encoding the immunostimulatory cytokine using intratumoral electroporation. The checkpoint inhibitor may be administered systemically or encoded on a plasmid and delivered using intratumoral electroporation. The checkpoint inhibitor may be delivered contemporaneously with or after treatment with the immunomodulatory cytokine.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: January 31, 2023
    Assignee: OncoSec Medical Incorporated
    Inventors: Robert H. Pierce, Adil Daud
  • Patent number: 11555207
    Abstract: Provided herein are CRIS-PR/Cas9 complexes and methods of using same.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 17, 2023
    Inventors: Tim Townes, Lei Ding, Chia-Wei Chang
  • Patent number: 11555180
    Abstract: Micro-Organosphers, including Patient-Derived Micro-Organospheres (PMOS s), apparatuses and methods of making them, and apparatuses and methods of using them. Also described herein are methods and systems for screening a patient using these Patient-Derived Micro-Organospheres, including personalized therapies.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: January 17, 2023
    Assignees: Xilis, Inc., Duke University
    Inventors: Xiling Shen, David Hsu, Jeffrey Motschman, Daniel Delubac, Zhaohui Wang
  • Patent number: 11547099
    Abstract: The invention relates to nucleic acid constructs for expression in mice for the production of heavy chain only antibodies and VH domains, transgenic mice, related methods and uses.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: January 10, 2023
    Assignee: Crescendo Biologies Limited
    Inventors: Yumin Teng, Joyce Young, Brian McGuinness, Mike Romanos, Marianne Brueggemann
  • Patent number: 11547730
    Abstract: Provided are methods and articles of manufacture for use in stem cell therapy, for the treatment of diseases or conditions of SCA. Particularly, the invention provides a method for treating SCA, comprising parenterally or locally administering an effective amount of stem cells as a unit dosage to a subject, wherein the administration is performed with one or more treatment cycles, wherein one treatment cycle comprises dosing three unit dosages each at a dosing interval of two to six weeks.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: January 10, 2023
    Inventors: Jennifer Hui-Chun Ho, Ryan Chang, Hsiu-Yu Lai, Wei-Kee Ong
  • Patent number: 11542524
    Abstract: Provided herein are methods and compositions for a suicide gene approach comprising an expression vector comprising a cell cycle-dependent promoter driving the expression of a suicide gene. Also provided herein are methods to render proliferative cells sensitive to a prodrug after transplantation but avoids expression of the suicide gene in post-mitotic cells, such as neurons.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 3, 2023
    Assignee: Research Development Foundation
    Inventors: Karl-Heinz Krause, Michel Dubois-Dauphin, Vannary Tieng Caulet